Science
Jemincare group has completed the Phase I clinical trial of its anti-SARS-CoV-2 neutralizing antibody JMB2002 – PR Newswire India
/PRNewswire/ — Recently, Jemincare group has declared that it has completed phase I clinical trial of self-developed novel coronavirus…
The clinical trial of JMB2002 was stated in January 2021. A single-center, randomized, double-blind, placebo-controlled, single-dose escalation phase I trial was designed to evaluate JMB2002’s tolerability, safety, pharmacokinetic characteristics and immunogenicity…
Continue Reading
